Catalyst Pharm Inc (CPRX) 0.76 $CPRX Catalyst

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Catalyst Pharm Inc (CPRX) 0.76 $CPRX

Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 10th, 2016
GlobeNewswire - Mon Aug 01, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release Second Quarter 2016 financial results after market close on Tuesday, August 9, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday, August 10th, 2016 to discuss the financial results and to provide a corporate update.
CPRX: 0.76 (+0.04)

Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 6.6%
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 7:25AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares jumped almost 7% on the day.
CPRX: 0.76 (+0.04), JNP: 7.50 (-0.04)

Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a confirmatory Phase 3 study protocol for Firdapse(R) (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). As part of the clinical protocol for the confirmatory study, Catalyst expects to initiate a small, single-center study with Firdapse during the second half of 2016. Catalyst also expects to announce additional information about the study design and timelines for the study once they are finalized.
CPRX: 0.76 (+0.04)

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.94 (-0.19), CPRX: 0.76 (+0.04), AKRX: 33.80 (-0.43), PCRX: 37.58 (+1.33)

Catalyst Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2016 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 7 at 4:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
CPRX: 0.76 (+0.04)

Catalyst (CPRX) Resorts to Layoffs for Firdapse Development
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:22AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) announced that it will reduce its workforce by approximately 30%. The move will primarily affect the commercial team.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), CPRX: 0.76 (+0.04), PFE: 37.31 (+0.42)

Catalyst Pharmaceutical's Firdapse Phase 3 Study Published in Muscle & Nerve
GlobeNewswire - Wed May 18, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported on the publication of detailed results from the LMS-002 Phase 3 study of amifampridine phosphate (Firdapse(R)) in patients with Lambert-Eaton myasthenic syndrome (LEMS). The study results were published in the May 2016 issue of Muscle & Nerve (volume 53, number 5), authored by Dr. Shin Oh, et al.
CPRX: 0.76 (+0.04)

Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
GlobeNewswire - Tue May 17, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the company is reducing its workforce by approximately 30%. The reduction in workforce, which affects employees from Catalyst's commercial team, is part of Catalyst's ongoing efforts to conserve cash as it works to complete the requirements for an NDA submission of Firdapse(R) (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).
CPRX: 0.76 (+0.04)

Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 45.29 (+0.54), CPRX: 0.76 (+0.04), SHPG: 194.00 (-0.12), ARQL: 1.68 (+0.02)

Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue May 10, 4:10PM CDT
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2016.
CPRX: 0.76 (+0.04)

Drug Stocks Reporting on May 10: XON, ARIA, CPRX & More
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:13AM CDT
What's in store for drug stocks, Jazz, Intrexon and others when they report their first-quarter results on May 10?
JNJ: 125.40 (+0.17), CPRX: 0.76 (+0.04), JAZZ: 150.53 (-0.44), XON: 27.38 (+2.05), AMGN: 174.16 (+2.13), ANAC: 99.06 (-0.14), ARIA: 9.71 (+0.20)

What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 31.15 (-0.27), CPRX: 0.76 (+0.04), JAZZ: 150.53 (-0.44), XON: 27.38 (+2.05)

Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Wednesday, May 11th, 2016
GlobeNewswire - Fri May 06, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release First Quarter 2016 financial results after market close on Tuesday, May 10, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday, May 11, 2016 to discuss the financial results and to provide a corporate update.
CPRX: 0.76 (+0.04)

Penny Stocks To Watch on Friday April 29
ACCESSWIRE - Fri Apr 29, 11:58AM CDT
MIAMI, FL / ACCESSWIRE / April 29, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. FREEF, KEG, CPRX, and HUSA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
CPRX: 0.76 (+0.04), KEG: 0.16 (-0.01)

The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), CPRX: 0.76 (+0.04), SRPT: 25.91 (+0.63), ABBV: 66.94 (+0.71)

Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News
Arpita Dutt - Zacks Investment Research - Wed Apr 27, 3:07PM CDT
While most major biotech stocks will be reporting results this week, Biogen (BIIB) kick-started the earnings season for the sector with an earnings beat.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), CPRX: 0.76 (+0.04), GILD: 80.46 (+0.99), SRPT: 25.91 (+0.63), ABBV: 66.94 (+0.71), REGN: 434.00 (+8.88)

Why Is Catyalyst Pharma (CPRX) Stock Crashing Today?
Ryan McQueeney - Zacks Investment Research - Tue Apr 26, 12:18PM CDT
Catalyst Pharmaceuticals (CPRX) stock crashed over 50% after the company announced that the FDA has requested additional data in its resubmission of a new drug application for Firdapse, a treatment for Lambert-Eaton myasthenic syndrome.
CPRX: 0.76 (+0.04)

Catalyst Pharmaceuticals Provides Regulatory Update on Firdapse
GlobeNewswire - Tue Apr 26, 5:55AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today provided an update on the content of the planned resubmission of the New Drug Application ("NDA" for Firdapse(R) (amifampridine phosphate), which currently has Breakthrough Therapy and Orphan Drug designations for Lambert-Eaton myasthenic syndrome (LEMS). Catalyst recently met with the Food and Drug Administration ("FDA" to obtain greater clarity regarding what will be required by the FDA to accept the Firdapse NDA for filing.
CPRX: 0.76 (+0.04)

Catalyst (CPRX) Posts In-Line Q4 Loss, FDA Meeting in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:29PM CDT
Catalyst Pharmaceuticals (CPRX) reported a loss of 7 cents per share in fourth-quarter 2015, wider than the year-ago loss of 5 cents but in line with the Zacks Consensus Estimate.
CPRX: 0.76 (+0.04), SCMP: 11.89 (+0.14), CORT: 5.77 (-0.03)

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Tue Mar 15, 3:30PM CDT
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the fourth quarter and the year-ended December 31, 2015.
CPRX: 0.76 (+0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 165

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 98

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 126

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 165

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Trua: Veteran-Led Service Offers Senior Living Help

Updated Category News Views 31

A New Chapter for Senior Living Guidance Life's complexities can be as tough as a two-dollar steak, and let's face it, senior living decisions often top that chart. Greater Boston gets a new lifeline with Trua of Greater Boston breaking into the scene. Not just any placement service, mind you. Run by Jersouk Touy and Jessie Marasco, it promises a blend of personalized,...

Continue Reading
Standex International Corporation Reports Q4 Fiscal 2025 Results

Updated Category News Views 162

Standex International Corporation to Announce Q4 2025 Results Standex International Corporation (NYSE: SXI) is set to unveil its financial results for the fourth quarter of fiscal year 2025 on Thursday. The report will be released after the market closes, providing investors and stakeholders with key insights into the company's performance. Key Details of the Announcement...

Continue Reading
Ireland's €3 Billion Bond Sale Highlights Strong Investor Demand

Updated Category News Views 136

Overview of Ireland's Successful Bond Issuance Dublin has recently seen an impressive move in the financial markets with the National Treasury Management Agency successfully issuing €3 billion in 30-year fixed-rate notes. This significant bond issuance demonstrates the strong appetite from investors without the need for stabilization measures, reflecting confidence in...

Continue Reading
Exciting Developments in Yukon Metals' Birch Copper-Gold Project

Updated Category News Views 196

Significant Updates from the Birch Copper-Gold Project Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) has recently announced thrilling developments concerning its 100%-owned Birch Copper-Gold Project, spanning 7,000 hectares. This project is located approximately 65 kilometres from Burwash Landing and 200 kilometres from Whitehorse. The current drill program aims...

Continue Reading
Krystal Biotech's Upcoming Presentation at Major Healthcare Event

Updated Category News Views 122

Krystal Biotech Set to Attend Major Healthcare Conference Krystal Biotech, Inc. (NASDAQ: KRYS), a company dedicated to leading the way in genetic medicine, has shared an exciting opportunity for both investors and the public. The Company will highlight its latest advancements at the upcoming 2024 Cantor Global Healthcare Conference in New York. This event stands out as...

Continue Reading